Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drug

EndpointsView source article

Part of story

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 20263 sourcesBiotech startup Drug development Cancer & Oncology Rare diseases Venture capital funding Clinical trials Autoimmune disease treatments Hematology & Blood Cancers

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

Other sources for this story

Axios

Dren Bio's $350m haul, Aspen IPO, Eversana deal

BioSpace

Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drug

Part of story

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

Other sources for this story

Dren Bio's $350m haul, Aspen IPO, Eversana deal

Dren Bio lands $350M to push rare blood cancer therapy toward market - BioSpace

Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drug

Part of story

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

Other sources for this story

Dren Bio's $350m haul, Aspen IPO, Eversana deal

Dren Bio lands $350M to push rare blood cancer therapy toward market - BioSpace